Response to recombinant erythropoietin alpha, without the adjunct of granulocyte-colony stimulating factor, is associated with a longer survival in patients with transfusion-dependent myelodysplastic syndromes

Leukemia Research

Volumn 34, Issue 8, 2010, Pages 981-985

  Musto, Pellegrino ^a   Villani, Oreste ^a   Martorelli, Maria Carmen ^a   Pietrantuono, Giuseppe ^a   Guariglia, Roberto ^a   Mansueto, Giovanna ^a   D'Auria, Fiorella ^a   Grieco, Vitina ^a   Bianchino, Gabriella ^a   Sparano, Anna ^a   Zonno, Antonia ^a   Lerose, Rosa ^b   Sanpaolo, Grazia ^c   Falcone, Antonietta ^c  

^a REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^b IRCCS   (Italy)

^c CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Anemia; Darbepoetin; G CSF; Myelodysplastic syndromes; Prognosis; Recombinant erythropoietin; Survival; Transfusion

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; DRUG SAFETY; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; BLOOD TRANSFUSION; DRUG THERAPY, COMBINATION; ERYTHROPOIETIN, RECOMBINANT; FEMALE; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77953561755     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.10.022     Document Type: Article

References (28)

1. Ross S.D., Allen I.E., Probst C.A., Sercus B., Crean S.M., Ranganathan G. Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis. Oncologist 2007, 12:1264-1273.
2. Moyo V., Lefebvre P., Duh M.S., Yektashenas B., Mundle S. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Annals of Hematology 2008, 8:527-536.
3. Mundle S., Lefebvre P., Vekeman F., Duh M.S., Rastogi R., Moyo V. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach. Cancer 2009, 115:706-715.
4. Alessandrino E.P., Amadori S., Barosi G., et al. Evidence- and consensus-based practice guidelines for the therapy of myelodysplastic syndromes: a statement from the Italian Society of Hematology. Haematologica 2002, 87:1286-1306.
5. Bowen D., Culligan D., Jowitt S., et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. British Journal of Haematology 2003, 120:187-200.
6. Rizzo J.D., Somerfield M.R., Hagerty K.L., et al. American Society of Hematology. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. Journal of Clinical Oncology 2008, 26:132-149.
7. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Myelodysplastic Syndromes (Version 1); 2009. Available from: http://www.nccn.org/.
8. Park S., Grabar S., Kelaidi C., et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 2008, 111:574-582.
9. Jädersten M., Malcovati L., Dybedal I., et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. Journal of Clinical Oncology 2008, 26:3607-3613.
10. Greenberg P.L., Sun Z., Miller K.B., et al. Treatment of myelodysplastic syndromes patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase III trial by the Eastern Cooperative Oncology Group (E1996). Blood 2009, 114:2393-2400.
11. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the classification of the myelodysplastic syndromes. British Journal of Haematology 1982, 51:189-199.
12. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
13. Swerdlow S.H., Campo E., Harris N.L., et al. WHO Classification of tumours of hematopoietic and lymphois tissues 2008, WHO/OMS Press, International Agency for Research on Cancer.
14. Malcovati L., Germing U., Kuendgen A., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. Journal of Clinical Oncology 2007, 25:3503-3510.
15. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. British Journal of Haematology 1998, 103:1070-1074.
16. Musto P., Sanpaolo G., D'Arena G., et al. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone. Haematologica 2001, 86:44-51.
17. Musto P., Falcone A., Sanpaolo G., et al. Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes. British Journal of Haematology 2003, 122:269-271.
18. Cheson B.D., Greenberg P.L., Bennett J.M., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108:419-425.
19. Wallvik J., Stenke L., Bernell P., Nordahl G., Hippe E., Hast R. Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes. European Journal of Haematology 2002, 68:180-185.
20. Jädersten M., Montgomery S.M., Dybedal I., Porwit-MacDonald A., Hellström-Lindberg E. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood 2005, 106:803-811.
21. Steinbrook R. Erythropoietin, the FDA, and oncology. New England Journal of Medicine 2007, 356:2448-2451.
22. Khuri F.R. Weighing the hazards of erythropoiesis stimulation in patients with cancer. New England Journal of Medicine 2007, 356:2445-2448.
23. Musto P. Recombinant erythropoietin and survival in myelodysplastic syndromes. Blood 2005, 106. [Abstract 2539].
24. Musto P. Revisiting the use of recombinant erythropoietin in myelodysplastic syndromes. Clinical Lymphoma 2005, 6:52-55.
25. Hellström-Lindberg E., Negrin R., Stein R., et al. Erythroid response to treatment with GCSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. British Journal of Haematology 1997, 99:344-351.
26. Howe R.B., Porwit-MacDonald A., Wanat R., Tehranchi R., Hellstrom-Lindberg E. The WHO classification of MDS does make a difference. Blood 2004, 103:3265-3270.
27. Hellström-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. British Journal of Haematology 1995, 89:67-71.
28. Malcovati L., Porta M.G., Pascutto C., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. Journal of Clinical Oncology 2005, 20:7594-7603.